{"id":26255,"date":"2026-06-25T17:30:00","date_gmt":"2026-06-25T15:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=feb893da5abf9aafb31151350341179f"},"modified":"2026-06-25T17:30:00","modified_gmt":"2026-06-25T15:30:00","slug":"asahi-kaseis-novel-forward-osmosis-membrane-distillation-system-installed-at-peptistars-api-manufacturing-facility-for-reduced-pharmaceutical-manufacturing-time","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=26255","title":{"rendered":"Asahi Kasei\u2019s Novel Forward Osmosis\u2013Membrane Distillation System Installed at Peptistar’s API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time"},"content":{"rendered":"

TOKYO--(BUSINESS WIRE)--Japanese pharmaceutical contract development and manufacturing organization (CDMO) <\/b>Peptistar<\/b><\/a> has integrated Asahi Kasei\u2019s novel forward osmosis\u2013membrane distillation (FO\u2013MD) system into its facility for trial production of active pharmaceutical ingredients (APIs). Asahi Kasei, a diversified global company, <\/b>announced in 2018<\/b><\/a> the development of a system that dehydrates and concentrates liquids without the application of heat or pressure. This reduces the number of freeze-drying batches and the amount of time required for freeze-drying, thereby shortening API manufacturing time. Peptistar has begun operation of the novel system at manufacturing scale as part of its evaluation toward GMP (Good Manufacturing Practice) production.<\/b><\/p><\/a><\/a><\/a><\/a>

\nRecently, demand for APIs has shifted from traditional, high-volume small molecules to a broader need across biologics, peptides, oligonucleotides, viral vectors, and more. API needs are becoming increasingly complex due to their high specificity and growing role in next-generation therapeutics.<\/p>

\nSome of the next-generation APIs such as peptides and oligonucleotides are heat sensitive. Their manufacturing processes have thus relied on the costly, time-consuming, and energy-intensive freeze-drying method, which can remove solvents without heating, to obtain APIs with high quality. Although the freeze-drying process can be shortened by concentrating the raw material solution to reduce the volume of liquid feed prior to the freeze-drying step, conventional concentration technologies such as vacuum distillation carry the risk of quality degradation due to heating, and the formation of precipitates caused by changes in solvent composition during the concentration step.<\/p>

\nAsahi Kasei\u2019s system for forward osmosis (FO) and membrane distillation (MD) addresses such manufacturing challenges by concentrating the raw material solution for pharmaceutical applications without applying heat or pressure. FO utilizes an osmotic pressure difference across a membrane to remove water from liquids, achieving highly concentrated API solutions under very mild conditions. This is in contrast to the tangential flow filtration (TFF) that is commonly used in API manufacturing, which can be challenging at high API concentration, as fouling or leaks can affect concentration efficiency and recovery rates. MD leverages a vapor pressure difference across a membrane to remove volatile components such as acetonitrile, alcohol, or ammonia, at or below room temperature.<\/p>

\nThe combination of FO and MD, both of which do not rely on heating or pressurization, enables the preparation of high-concentration solutions for freeze-drying while maintaining control of ingredient composition and avoiding precipitation. This FO\u2013MD system allows short freeze-drying time, resulting in high productivity manufacturing of APIs at high purity and high yield. The FO\u2013MD system installed at Peptistar\u2019s manufacturing facility is being operated at manufacturing scale as part of its evaluation toward GMP production. The system can be used with batches of up to 100 L, and is designed to be compatible with GMP-compliant operation.<\/p>

\nAsahi Kasei looks forward to studying the prospects for future commercialization of the FO\u2013MD system. This aligns with the company\u2019s broader structural transformation, positioning Life Science as a Growth Potential business in its medium-term management plan<\/a>.<\/p>

\nAbout Asahi Kasei\n<\/b>Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world\u2019s challenges across its three business sectors: Healthcare, Homes, and Material. For more information, visit https:\/\/www.asahi-kasei.com\/<\/a>.<\/p> Contacts<\/b>

\nAsahi Kasei America Inc.<\/b>Christian OKeefe\nchristian.okeefe@ak-america.com<\/a>\nAsahi Kasei Europe GmbH<\/b>Sebastian Schmidt\nsebastian.schmidt@asahi-kasei.eu<\/a><\/p>","protected":false},"excerpt":{"rendered":"

TOKYO–(BUSINESS WIRE)–Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei\u2019s novel forward osmosis\u2013membrane distillation (FO\u2013MD) system into its facility for trial production of activ…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-26255","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/26255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26255"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/26255\/revisions"}],"predecessor-version":[{"id":26256,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/26255\/revisions\/26256"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}